Abstract
Background. The endemic coronaviruses OC43, HKU1, NL63, and 229E cause cold-like symptoms and are related to SARS-CoV-2, but their natural histories are poorly understood. In a cohort of children followed from birth to 4 years, we documented all coronavirus infections, including SARS-CoV-2, to understand protection against subsequent infections with the same virus (homotypic immunity) or a different coronavirus (heterotypic immunity). Methods. Mother–child pairs were enrolled in metropolitan Cincinnati during the third trimester of pregnancy in 2017-2018. Mothers reported their child’s sociodemographics, risk factors, and weekly symptoms. Mid-turbinate nasal swabs were collected weekly. Blood was collected at 6 weeks, 6, 12, 18, 24 months, and annually thereafter. Infections were detected by testing nasal swabs by an RT-PCR multi-pathogen panel and by serum IgG responses. Health care visits were documented from pediatric records. Analysis was limited to 116 children with high sample adherence. Reconsent for monitoring SARS-CoV-2 infections from June 2020 through November 2021 was obtained for 74 (64%) children. Results. We detected 345 endemic coronavirus infections (1.1 infections/child-year) and 21 SARS-CoV-2 infections (0.3 infections/child-year). Endemic coronavirus and SARS-CoV-2 infections were asymptomatic or mild. Significant protective homotypic immunity occurred after a single infection with OC43 (77%) and HKU1 (84%) and after two infections with NL63 (73%). No heterotypic protection against endemic coronaviruses or SARS-CoV-2 was identified. Conclusions. Natural coronavirus infections were common and resulted in strong homotypic immunity but not heterotypic immunity against other coronaviruses, including SARS-CoV-2. Endemic coronavirus and SARS-CoV-2 infections in this US cohort were typically asymptomatic or mild.
Original language | English |
---|---|
Pages (from-to) | 265-273 |
Number of pages | 9 |
Journal | Journal of the Pediatric Infectious Diseases Society |
Volume | 13 |
Issue number | 5 |
DOIs | |
State | Published - May 1 2024 |
Bibliographical note
Publisher Copyright:© The Author(s) 2024.
Funding
Financial support. The PREVAIL Cohort was supported by a cooperative agreement from the US Centers for Disease Control and Prevention (IP16-004), with additional funding for serologic testing provided by the National Instititute for Allergic and Infectious Diseases (U01A1144673). Additional support was provided by the National Institute of Environmental Health Sciences (5 T32 ES 10957-18) and the National Center for Advancing Translational Sciences (2UL2TROO1425-05A1).
Funders | Funder number |
---|---|
Centers for Disease Control and Prevention | IP16-004 |
Centers for Disease Control and Prevention | |
National Instititute for Allergic and Infectious Diseases | U01A1144673 |
National Institutes of Health/National Institute of Environmental Health Sciences | 5 T32 ES 10957-18 |
National Institutes of Health/National Institute of Environmental Health Sciences | |
National Center for Advancing Translational Sciences (NCATS) | 2UL2TROO1425-05A1 |
National Center for Advancing Translational Sciences (NCATS) |
Keywords
- 229E
- birth cohort
- endemic coronaviruses
- HKU1
- immunity
- natural history
- NL63
- OC43
- pediatrics
- preventive efficacy
- SARS-CoV-2
ASJC Scopus subject areas
- General Medicine